LRMR (STOCKS)
Larimar Therapeutics, Inc. Common Stock
$4.880000
+0.030000 (+0.62%)
Prev close: $4.850000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Carole S. Ben-Maimon
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $505.05M
- Employees
- 65
- P/E (TTM)
- -2.20
- P/B (TTM)
- 5.18
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
9
Strong Buy
7
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$-0.73 | $-0.52 | -0.2129 | -41.17% |
|
Sep 2025 (Q3)
|
$-0.61 | $-0.41 | -0.1979 | -48.02% |
|
Jun 2025 (Q2)
|
$-0.41 | $-0.49 | +0.0798 | +16.29% |
|
Mar 2025 (Q1)
|
$-0.46 | $-0.43 | -0.0334 | -7.83% |
Financial Statements
| Revenues | $0.00 |
| Nonoperating Income/Loss | $6.82M |
| Operating Expenses | $172.50M |
| Research and Development | $154.22M |
| Other Operating Expenses | $18.27M |
| Operating Income/Loss | -$172.50M |
| Income/Loss From Continuing Operations After Tax | -$165.67M |
| Income/Loss From Continuing Operations Before Tax | -$165.67M |
| Income Tax Expense/Benefit | $0.00 |
| Net Income/Loss | -$165.67M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$165.67M |
| Net Income/Loss Available To Common Stockholders, Basic | -$165.67M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Assets | $145.84M |
| Current Assets | $142.02M |
| Cash | $136.90M |
| Other Current Assets | $5.12M |
| Noncurrent Assets | $3.82M |
| Fixed Assets | $622.00K |
| Other Non-current Assets | $3.20M |
| Liabilities | $67.76M |
| Current Liabilities | $64.80M |
| Accounts Payable | $5.22M |
| Wages | $3.78M |
| Other Current Liabilities | $55.80M |
| Noncurrent Liabilities | $2.96M |
| Equity | $78.09M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $78.09M |
| Liabilities And Equity | $145.84M |
| Net Cash Flow From Operating Activities | -$113.20M |
| Net Cash Flow From Operating Activities, Continuing | -$113.20M |
| Net Cash Flow From Investing Activities | $100.31M |
| Net Cash Flow From Investing Activities, Continuing | $100.31M |
| Net Cash Flow From Financing Activities | $65.09M |
| Net Cash Flow From Financing Activities, Continuing | $65.09M |
| Net Cash Flow | $52.19M |
| Net Cash Flow, Continuing | $52.19M |
| Comprehensive Income/Loss | -$165.77M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$165.77M |
| Other Comprehensive Income/Loss | -$94.00K |
| Other Comprehensive Income/Loss Attributable To Parent | -$94.00K |